Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

This study will investigate the safety and effectiveness of a new combination treatment for patients with advanced bile duct cancer. The treatment combines standard chemotherapy drugs (gemcitabine and cisplatin) with two additional medications: adebrelimab and simvastatin. All participants in this study will receive the same four-drug combination. Researchers will closely monitor patients to see how well the tumors shrink, how long the treatment keeps the cancer from growing, and what side effects occur. The study is exploratory, meaning it aims to gather initial data on whether this four-drug combination is a promising approach for treating advanced biliary tract cancer.

NCT Number	NCT07392541
Lead Sponsor	Tongji Hospital
Conditions	Advanced Biliary Tract Carcinoma
Enrollment	29 participants
Start Date	2026-01-30
Primary Completion	2028-01-30 (estimated)
Study Completion	2028-01-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-23